Status: current, Not sufficiently defined by necessary conditions definition status. Date: 25-Jun 2014. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 80038101000001112 | Umeclidinium bromide + Vilanterol (product) | en | Fully specified name | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| 80038201000001117 | Umeclidinium bromide + Vilanterol | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Umeclidinium bromide + Vilanterol | Is a | Product containing beta-2 adrenergic receptor agonist | true | Inferred relationship | Existential restriction modifier | ||
| Umeclidinium bromide + Vilanterol | Is a | Product containing muscarinic receptor antagonist | true | Inferred relationship | Existential restriction modifier | ||
| Umeclidinium bromide + Vilanterol | Is a | Virtual therapeutic moiety | true | Inferred relationship | Existential restriction modifier | ||
| Umeclidinium bromide + Vilanterol | Has active ingredient | Substance with muscarinic receptor antagonist mechanism of action | true | Inferred relationship | Existential restriction modifier | ||
| Umeclidinium bromide + Vilanterol | Has active ingredient | Substance with beta-2 adrenergic receptor agonist mechanism of action | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Umeclidinium bromide 65micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler | Is a | True | Umeclidinium bromide + Vilanterol | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR